ArticleFuture neurology2009
Clinical and molecular aspects of varicella zoster virus infection.
Article in Future neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Pooled it
- Rapid Resolution of Grade VI Facial Nerve Paralysis in Ramsay Hunt Syndrome With Prompt Dual Antiviral-Corticosteroid Therapy: A Case Report.Clinical case reports · 2026Article
- Varicella zoster virus-related myelitis: a case series and literature review.Virology journal · 2026Review
- Nectin-1 Is an Entry Mediator for Varicella-Zoster Virus Infection of Human Neurons.Journal of virology · 2021Article
- Video Anthology of Movement Disorders Due to Infections in South Asia.Movement disorders clinical practice · 2021Review
- Herpes Zoster Vaccine Live and Risk of Stroke Among Medicare Beneficiaries: A Population-Based Cohort Study.Stroke · 2021Article
- Article
- An Unusual Presentation of Herpes Zoster.Kansas journal of medicine · 2020Article
- Varicella Zoster Virus Vasculitis and Adult Cerebrovascular Disease.The Neurohospitalist · 2019Review
- Longitudinal Extensive Transverse Myelitis in an Immunocompetent Older Individual-A Rare Complication of Varicella-Zoster Virus Reactivation.Medicina (Kaunas, Lithuania) · 2019Article
- The Role of the Microbiota in the Diabetic Peripheral Artery Disease.Mediators of inflammation · 2019Review
- Effectiveness of continuous epidural analgesia on acute herpes zoster and postherpetic neuralgia: A retrospective study.Medicine · 2018Observational
- Role of the JNK Pathway in Varicella-Zoster Virus Lytic Infection and Reactivation.Journal of virology · 2017Article
- Association between Bacterial Infection and Peripheral Vascular Disease: A Review.The International journal of angiology : official publication of the International College of Angiology, Inc · 2016Review
- Incidence of herpes zoster and associated events including stroke--a population-based cohort study.BMC infectious diseases · 2015Article
- Childhood infections and trauma as risk factors for stroke.Current cardiology reports · 2014Review
- Animal models of varicella zoster virus infection.Pathogens (Basel, Switzerland) · 2013Review
- Virus reactivation: a panoramic view in human infections.Future virology · 2011Article
- Analysis of human alphaherpesvirus microRNA expression in latently infected human trigeminal ganglia.Journal of virology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
A declining cell-mediated immunity to varicella zoster virus (VZV) with advancing age or immunosuppression results in virus reactivation from latently infected human ganglia anywhere along the neuraxis. Virus reactivation produces zoster, often followed by chronic pain (postherpetic neuralgia or PHN) as well as vasculopathy, myelopathy, retinal necrosis and cerebellitis. VZV reactivation also produces pain without rash (zoster sine herpete). Vaccination after age 60 reduces the incidence of shingles by 51%, PHN by 66% and the burden of illness by 61%. However, even if every healthy adult over age 60 years is vaccinated, there would still be about 500,000 zoster cases annually in the United States alone, about 200,000 of whom will experience PHN. Analyses of viral nucleic acid and gene expression in latently infected human ganglia and in an animal model of varicella latency in primates are serving to determine the mechanism(s) of VZV reactivation with the aim of preventing reactivation and the clinical sequelae.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.